Validation of the DNA Damage Immune Response Signature in Patients With Triple-Negative Breast Cancer From the SWOG 9313c Trial

Priyanka Sharma,William E. Barlow,Andrew K. Godwin,Eileen E. Parkes,Laura A Knight,Steven M. Walker,Richard D. Kennedy,D. P. Harkin,Gemma E Logan,Christopher Steele,Shauna Lambe,Sunil Badve,Yesim Gökmen-Polar,Harsh B. Pathak,Kamilla Isakova,Hannah M. Linden,Peggy L. Porter,Lajos Pusztai,Alastair M. Thompson,Debu Tripathy,Gabriel N. Hortobagyi,Daniel F. Hayes

Validation of the DNA Damage Immune Response Signature in Patients With Triple-Negative Breast Cancer From the SWOG 9313c Trial

2019

PURPOSETo independently validate two biomarkers, a 44-gene DNA damage immune response (DDIR) signature and stromal tumor-infiltrating lymphocytes (sTILs), as prognostic markers in patients with tri...

Keywords:

Oncology
Pathology
Immune system
Stromal cell
Internal medicine
Triple-negative breast cancer
DNA damage
Biomarker (medicine)
Medicine
in patient
disease free survival
Transcriptome

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations